Alembic Pharmaceuticals Management
Management criteria checks 3/4
Alembic Pharmaceuticals' CEO is Chirayu Amin, appointed in Apr 2016, has a tenure of 7.92 years. total yearly compensation is ₹88.00M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.13% of the company’s shares, worth ₹4.06B. The average tenure of the management team and the board of directors is 8.4 years and 13 years respectively.
Key information
Chirayu Amin
Chief executive officer
₹88.0m
Total compensation
CEO salary percentage | 100.0% |
CEO tenure | 7.9yrs |
CEO ownership | 2.1% |
Management average tenure | 8.4yrs |
Board average tenure | 13yrs |
Recent management updates
Recent updates
Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt
May 05Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jan 17Are Alembic Pharmaceuticals Limited (NSE:APLLTD) Investors Paying Above The Intrinsic Value?
Dec 17These 4 Measures Indicate That Alembic Pharmaceuticals (NSE:APLLTD) Is Using Debt Reasonably Well
Sep 23Is There An Opportunity With Alembic Pharmaceuticals Limited's (NSE:APLLTD) 27% Undervaluation?
Sep 02Here's Why I Think Alembic Pharmaceuticals (NSE:APLLTD) Might Deserve Your Attention Today
Jun 16Alembic Pharmaceuticals (NSE:APLLTD) Has A Pretty Healthy Balance Sheet
May 25CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | ₹6b |
Sep 30 2023 | n/a | n/a | ₹5b |
Jun 30 2023 | n/a | n/a | ₹5b |
Mar 31 2023 | ₹88m | ₹88m | ₹3b |
Dec 31 2022 | n/a | n/a | ₹2b |
Sep 30 2022 | n/a | n/a | ₹3b |
Jun 30 2022 | n/a | n/a | ₹3b |
Mar 31 2022 | ₹280m | ₹80m | ₹5b |
Dec 31 2021 | n/a | n/a | ₹8b |
Sep 30 2021 | n/a | n/a | ₹9b |
Jun 30 2021 | n/a | n/a | ₹10b |
Mar 31 2021 | ₹315m | ₹65m | ₹11b |
Dec 31 2020 | n/a | n/a | ₹12b |
Sep 30 2020 | n/a | n/a | ₹11b |
Jun 30 2020 | n/a | n/a | ₹10b |
Mar 31 2020 | ₹265m | ₹65m | ₹8b |
Dec 31 2019 | n/a | n/a | ₹7b |
Sep 30 2019 | n/a | n/a | ₹7b |
Jun 30 2019 | n/a | n/a | ₹6b |
Mar 31 2019 | ₹255m | ₹55m | ₹6b |
Dec 31 2018 | n/a | n/a | ₹6b |
Sep 30 2018 | n/a | n/a | ₹5b |
Jun 30 2018 | n/a | n/a | ₹4b |
Mar 31 2018 | ₹220m | ₹55m | ₹4b |
Dec 31 2017 | n/a | n/a | ₹4b |
Sep 30 2017 | n/a | n/a | ₹4b |
Jun 30 2017 | n/a | n/a | ₹4b |
Mar 31 2017 | ₹205m | ₹55m | ₹4b |
Compensation vs Market: Chirayu's total compensation ($USD1.06M) is above average for companies of similar size in the Indian market ($USD443.72K).
Compensation vs Earnings: Chirayu's compensation has been consistent with company performance over the past year.
CEO
Chirayu Amin (77 yo)
7.9yrs
Tenure
₹88,000,000
Compensation
Mr. Chirayu Ramanbhai Amin, M.B.A. (U.S.A.), has been Chief Executive Officer of Alembic Pharmaceuticals Limited since April 27, 2016. Mr. Amin served as Managing Director of Alembic Pharmaceuticals Limite...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman & CEO | 7.9yrs | ₹88.00m | 2.13% ₹ 4.1b | |
MD & Executive Director | 8.9yrs | ₹122.20m | 0.59% ₹ 1.1b | |
MD & Executive Director | 8.9yrs | ₹122.20m | 0.51% ₹ 974.2m | |
Director of Finance | no data | ₹56.90m | no data | |
President of Operations | no data | no data | no data | |
Chief Scientific Officer | no data | ₹8.41m | no data | |
Company Secretary & Compliance Officer | less than a year | no data | no data | |
Chief Business Development Officer | no data | ₹8.30m | 0.51% ₹ 974.2m | |
Senior Vice President of Human Resources | no data | no data | no data | |
Senior Vice President | no data | ₹8.12m | no data | |
Senior Vice President of Finance | no data | ₹9.20m | no data | |
Senior Vice President of Supply Chain | no data | no data | no data |
8.4yrs
Average Tenure
62.5yo
Average Age
Experienced Management: APLLTD's management team is seasoned and experienced (8.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman & CEO | 13.8yrs | ₹88.00m | 2.13% ₹ 4.1b | |
MD & Executive Director | 13yrs | ₹122.20m | 0.59% ₹ 1.1b | |
MD & Executive Director | 10.8yrs | ₹122.20m | 0.51% ₹ 974.2m | |
Director of Finance | 13.8yrs | ₹56.90m | no data | |
Independent Non-Executive Director | 9.1yrs | ₹1.83m | no data | |
Independent Non-Executive Director | 13yrs | ₹1.91m | no data | |
Independent Non-Executive Director | 13yrs | ₹1.87m | 0.011% ₹ 21.5m | |
Independent Non-Executive Director | 13yrs | ₹1.87m | 0.0024% ₹ 4.7m | |
Independent Director | 2.1yrs | ₹1.82m | no data | |
Additional Independent Director | less than a year | no data | no data |
13.0yrs
Average Tenure
65.5yo
Average Age
Experienced Board: APLLTD's board of directors are seasoned and experienced ( 13 years average tenure).